Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | Industry Therapeutic Update from Bristol Myers Squibb and Johnson & Johnson Alliance: Unmet Needs in Stroke Prevention for Patients with Atrial Fibrillation and Secondary Stroke: Exploring FXI/FXIa Inhibition

Saturday 04/18/26
06:00 PM - 08:00 PM CDT Add To Calendar
Marriott Marquis Chicago | Great Lakes ABC
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
General Neurology
The objective of the BMS/J&J ITU is to address the unmet needs within stroke prevention for patients with atrial fibrillation or secondary stroke.
No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM CDT Speaker Industry Therapeutic Update from Bristol Myers Squibb: Addressing Gaps in Stroke Prevention for Atrial Fibrillation and Secondary Stroke: The Evolving Role of FXI/XIa Inhibition
Faculty Disclosures
Gregory W. Albers, MD No disclosure on file
Pierre Fayad, MD, FAHA, FÂ鶹´«Ã½Ó³»­ Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.